Benefits of Metformin in Attenuating the Hallmarks of Aging

Ameya S. Kulkarni, Sriram Gubbi, Nir Barzilai

Research output: Contribution to journalReview articlepeer-review

246 Scopus citations


Metformin is the first drug to be tested for its age-targeting effects in a large clinical trial. In this perspective, Kulkarni et al. review how metformin acts on its primary and secondary targets to attenuate the hallmarks of aging, highlighting its utility as an effective gerotherapeutic intervention.

Original languageEnglish (US)
Pages (from-to)15-30
Number of pages16
JournalCell metabolism
Issue number1
StatePublished - Jul 7 2020


  • TAME
  • aging
  • aging hallmarks
  • health span
  • longevity
  • metabolism
  • metformin

ASJC Scopus subject areas

  • Physiology
  • Molecular Biology
  • Cell Biology


Dive into the research topics of 'Benefits of Metformin in Attenuating the Hallmarks of Aging'. Together they form a unique fingerprint.

Cite this